Radiopharmaceutical is a radioactive pharmaceutical agent which is used diagnostic or therapeutic procedures. A radiopharmaceutical is made up of two components that are drug component and radioactive component. This radioactive component consists of radioistopes which emits gamma rays which help in diagnostic. Moreover, these radioisotopes emits short range particles which lose their power in short distance which causes a lot of cell destruction. Radiopharmaceutical have been used effectively for cancer cell destruction, pain treatment in palliative care for bone cancer or arthritis.

The growth of global radiopharmaceutical market is attributed to the factors such as increase in the number of patients of cancer, dementia and Alzhimer’s Parkinson and increase in demand from developing countries attributed to non-invasiveness procedures. Moreover factors such as advances in radiotracers is also fueling the growth ofglobal radiopharmaceutical market.However, side effects due to consumption of high doses and stringent regulatory guidelines restraints the growth of market.

The global radiopharmaceuticals market is segmented on the basis of product type, application and geography. On the basis on product type the market is segmented into diagnostic and therapeutic products. Diagnostic products market is further classified into SPECT and PET isotopes. Therapeutics market segment is further classified alpha emitters, beta emitters, and brachytherapy. On the basis of application market is segmented into cardiology, neurology, oncology, thyroid, bone metastasis, and endocrine tumors. Geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and rest of the world (RoW).